The fFN test is the only named biomarker test recommended in the NICE guidelines for the risk assessment of preterm labour and birth1 and comes with a strong body of evidence supporting its use in the clinical setting.
fFN testing has been shown to precisely measure the concentration of the fFN protein to help quantify the risk of preterm labour and birth in both patients who have symptoms of preterm labour and those at high-risk.2
In this section you will find links to clinical papers, including four reviewed clinical papers that discuss the development and provision of the fFN test.
This link will take you to the information intended for healthcare professionals outside of the United States. Because these pages concern the international distribution activities of the QuikCheckTM fFN Test, which are not necessarily governed by US law, contents of the international pages may contain information that does not pertain to US users, including certain products that may not be cleared or approved by US Food & Drug Administration for promotion or sale in the United States. Click “Continue” to proceed, or click “Cancel” to remain in the US site.
Caution: The QuikCheck fFNTest is not sold or offered for sale in the United States or Canada.
Hologic, Inc. does not review nor control the content on non-Hologic websites. This link does not constitute an endorsement by Hologic of the content of the site you are about to visit. Hologic privacy procedures do not apply to the owners of a non-Hologic website.